has received the Kyoto Prize in Advanced Technology, which includes a cash award of $460,000, from the Inamori Foundation
for “significant contributions to the scientific, cultural and spiritual development of humanity,” according to a statement.
Karp, a professor of electrical engineering and computer sciences at the University of California, Berkeley, and a senior research scientist at the International Computer Science Institute, was recognized for his contributions to the theory of computational complexity, which has increased problem-solving efficiency. He has developed creating many practical computer algorithms and also “exerted profound influence on the guiding principles behind the analysis and design of algorithms used in many scientific disciplines,” the foundation said.
Karp has more recently worked in the field of computational biology, where he has developed algorithms for constructing physical maps of DNA targets and methods for classifying biological samples on the basis of gene expression data. His current interests are in the application of combinatorial and probabilistic methods to finding hidden patterns in gene expression data and discovering the structure of genetic regulatory networks.
The Inamori Foundation was founded in 1984 by Kazuo Inamori, the founder and chairman emeritus of Kyocera and KDDI Corporation and the prize was established one year later.
Upstream Biosciences has appointed chemoinformaticist Alexander Tropsha from the University of North Carolina to its scientific advisory board. He will advise on the development of compounds to treat diseases common to tropical regions of the world, such as parasitic diseases.
Tropsha is professor of medicinal chemistry and chair of the division of medicinal chemistry and natural products of UNC's Eshelman School of Pharmacy. His current research interests include computer-aided drug design, chemoinformatics, structural bioinformatics, and molecular simulations of proteins and peptides.
Upstream Biosciences in Vancouver is a drug developer focused on developing and commercializing drug candidates to treat tropical diseases, including malaria, trypanosomiasis, and leishmaniasis.